Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds

GLEN ALLEN, Va., Nov. 26, 2025 ( GLOBE NEWSWIRE ) -- Adial Pharmaceuticals, Inc. ( NASDAQ: ADIL ) ( "Adial" or the "Company" ) , a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced its ...

Strategic Advancements and Collaborations Propel Adial Pharmaceuticals’ Buy Rating

Jason McCarthy from Maxim Group maintains a Buy rating for Adial Pharmaceuticals with a $1.50 price target. The rating is based on strategic advancements, including a Phase 3 study for AD04 in alcohol use disorder, collaboration with Genomind for a genetic test, and a cautious financial strategy. These factors contribute to an optimistic outlook for AD04's market potential in the US and EU by 2030.

Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Adial Pharmaceuticals reported its Q3 2025 financial results, showing a decrease in cash reserves to $4.6 million and a net loss of $1.8 million, improved from $2.2 million in Q3 2024. The company is advancing its lead drug, AD04, for Alcohol Use Disorder, following a successful FDA meeting. Strategic initiatives include a provisional patent update and a partnership with Genomind. CEO Cary Claiborne expressed confidence in FDA approval and commercialization, with plans for a Phase 3 program and strategic partnerships.

Adial Pharmaceuticals reports Q3 net loss of $1.8 million

Adial Pharmaceuticals reported a Q3 2025 net loss of $1.8 million, down from $2.2 million in Q3 2024. R&D expenses decreased by 50%, while general and administrative expenses rose by 5%. Cash reserves fell to $4.6 million, expected to fund operations until Q2 2026. Business updates include a provisional patent for AD04 and progress toward FDA approval.

Adial Pharmaceuticals | 10-Q: FY2025 Q3 Revenue: USD 0